Rigel Pharmaceuticals (RIGL) opened 2026 with Q1 revenue of US$58.8 million and basic EPS of US$0.47, alongside trailing 12‑month revenue of US$299.8 million and basic EPS of US$20.08, set against very large year over year earnings growth and higher net profit margins in the latest trailing figures. Over recent quarters the company has seen revenue move from US$57.6 million in Q4 2024 to US$53.3 million in Q1 2025, US$101.7 million in Q2 2025, US$69.5 million in Q3 2025 and US$69.8 million in Q4 2025. Basic EPS shifted from US$0.81 to US$0.64, US$3.33, US$1.55, US$14.72 and now US$0.47 as profitability remains closely tied to margin shape. For investors, the mix of very strong trailing earnings growth, higher margins and a substantial share of non cash earnings places the quality and durability of those margins at the center of the current earnings narrative.

See our full analysis for Rigel Pharmaceuticals.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely held narratives around Rigel, and where the data starts to push back on those stories.

TTM earnings surge vs modest 6.3% revenue growth

• Over the last 12 months, revenue grew about 6.3% per year while net income reached US$364.2 million on US$299.8 million of revenue, highlighting that profit growth far outpaced topline growth.
• Consensus narrative points to expanding products and partnerships as drivers of future revenue, yet the current figures show only modest revenue growth alongside very large earnings expansion, which raises questions about how much of that profit strength comes from sustainable product sales versus items like non cash collaboration income that may not repeat.
  • The recent large year over year earnings increase and 18.3% trailing net margin sit beside a revenue growth rate that remains below the 11.3% US market forecast. A balanced view around long term growth has to account for this gap.
  • Analysts expecting revenue to grow about 3.5% annually while earnings are expected to decline over time are effectively saying the current profit levels implied by the US$364.2 million of trailing net income may not be the baseline going forward. This is a key tension for anyone leaning on the consensus narrative.

Low 1.4x P/E and DCF fair value gap

• With the stock at US$26.67, Rigel is reported to trade on a 1.4x P/E compared with 17.6x for the US Biotechs industry and 54.4x for peers, and at about a 73.6% discount to the stated DCF fair value of US$101.17.
• Bulls argue that expansion of the commercial portfolio and international reach could justify a much higher valuation, yet the same data set shows analysts expect earnings to decline around 33% per year over the next three years. The current low P/E and large gap to DCF fair value therefore depend heavily on how durable investors think today’s US$20.08 of trailing EPS really is.
  • The bullish narrative leans on potential revenue growth well above past 6.3% trailing revenue growth, while the provided forecasts instead flag falling earnings. This gives you a concrete check on how aggressive the bullish case is relative to the numbers in hand.
  • At the same time, the stock trades far below both the DCF fair value and the single allowed analyst target of US$50.80, so anyone reading the bullish view can see that valuation arguments are anchored in a meaningful gap between price and these reference values, not just in growth stories.

On these numbers, bulls see a stock priced as if the recent US$364.2 million of earnings will fade quickly, while the bullish narrative suggests more staying power and room for the valuation to rerate. It is worth reading the full bullish case before deciding where you stand. 🐂 Rigel Pharmaceuticals Bull Case

High non cash earnings and forecast EPS decline

• Trailing results combine an 18.3% net margin and very large year over year earnings growth with what is described as a high level of non cash earnings and analyst forecasts of about a 33% annual earnings decline over the next three years.
• Bears highlight that recent profit includes sizeable non cash collaboration income and other non recurring items, and the forecast EPS decline backs that caution because it suggests the US$364.2 million of trailing net income and US$20.08 of trailing EPS are unlikely to be repeated at the same level once those non cash contributions and one off items roll out of the figures.
  • The bearish narrative focuses on concentration in a narrow product set and pressure on small molecule pricing, and the presence of high non cash earnings in the trailing numbers fits with the idea that underlying recurring profitability may be lower than headline EPS implies.
  • With revenue growth running below the broader US market forecast and analysts expecting shrinking margins from current levels, the numbers give bears concrete support for questioning both the durability of current margins and the sustainability of the very strong trailing earnings.

If you want to see how these risks are framed by more cautious investors and how they interpret the non cash earnings and forecast decline, it is worth reading the bearish case alongside the raw numbers. 🐻 Rigel Pharmaceuticals Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Rigel Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, does the balance of this story match your own read of the numbers, or not quite yet? To pressure test the bullish and bearish angles against the underlying data, take a closer look at the 3 key rewards and 2 important warning signs.

See What Else Is Out There

Rigel’s mix of modest 6.3% revenue growth, high non cash earnings and forecast EPS decline suggests its current profit strength may be less durable than headlines imply.

If you are uneasy about that earnings quality trade off and want stocks where valuations appear supported by more recurring fundamentals, check out the 47 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.